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Unusual and discrepant ABO phenotypes are often due to genetic 
variants that lead to altered levels or activity of ABO transferases 
and consequently to altered expression of ABO antigens. This 
report describes eight genetic alterations found in 15 cases with 
reduced or undetectable expression of ABO antigens. Forward 
and reverse ABO grouping was performed by standard gel or tube 
methods. Adsorption-heat elution and saliva testing for H and 
A substances followed the AABB technical manual procedures. 
Genomic DNA extracted from whole blood was PCR-amplified to 
cover the entire ABO coding sequence, splice junctions, proximal 
promoter, and intron 1 enhancer. Amplification products were 
sequenced by next-generation or Sanger dideoxy methods, 
either directly or after cloning into a bacterial plasmid vector. 
Eight unreported alleles were found in the 15 cases analyzed. 
Alleles ABO*A(28+1C) and ABO*A(29–5G) harbor variants that 
alter the consensus sequence at the intron 1 donor and acceptor 
splice sites, respectively. The other alleles harbor variants that 
alter the consensus sequence at transcription factor–binding 
sites in the intron 1 enhancer: specifically, ABO*A(28+5792T), 
ABO*A(28+5859A), and ABO*A(28+5860G) at GATA-1 sites; 
ABO*B(28+5877T) and ABO*B(28+5878G) at a RUNX1 site; 
and ABO*A(28+5843A) at or near a C/EBP site. Molecular 
and serologic characterization of ABO alleles can help in their 
future identification and in the resolution of discrepancies. 
Immunohematology 2021;37:178–184. DOI: 10.21307/
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Genetic variants that lead to altered expression of ABO 
antigens have been found within the coding sequence, splice 
junctions, proximal promoter, and intron 1 enhancer of ABO 
transferase genes. ABO intron 1 spans 13 kb (approximately 
two-thirds of the gene’s length) and harbors variants at 
sequences that play a role in either mRNA maturation or the 
enhancement of transcription: in particular, variants near exon 
1 that alter the donor splice site and variants in the enhancer 
element located 5.7–6.0 kb from exon 1 that delete or alter 
transcription factor binding sites.1–14 These variants are mostly 
single-nucleotide substitutions, with a few large deletions and 
small indels, and have been found in both A and B transferase 
genes. Variant ABO alleles are often found in samples with 
unusual agglutination patterns (weak, mixed field) and in 
samples with typing discrepancies (forward versus reverse 
typing, gel versus tube methods, monoclonal versus polyclonal 
reagents). This report describes eight new alleles with single-
nucleotide substitutions found in 15 samples with unusual or 
discrepant ABO serology.
Materials and Methods
Serology was performed by standard methods. Reagents 
and manufacturers are listed in Table 1. For molecular 
assays, genomic DNA was extracted from whole blood by a 
matrix affinity method (Qiagen, Germantown, MD). Sanger 
sequencing included ABO exons 1–7 and flanking intron 
regions, approximately 170 bp of proximal promoter, and 
approximately 580 bp of the intron 1 enhancer region. 
Sequencing was performed on a Genetic Analyzer instrument, 
and the data were analyzed with SeqScape software (Applied 
Biosystems, Waltham, MA). Next-generation sequencing 
included ABO exons 1–7 and flanking intron regions, approx-
imately 170 bp of proximal promoter, and approximately 310 
bp of the intron 1 enhancer region. Sequencing was performed 
on an MiSeq instrument (Illumina, Foster City, CA), and 
the data were analyzed with custom-developed software.15 
Variant numbering is based on the GRCh38.p13 assembly 
(NCBI nucleotide ID: NC_000009.12), with ABO intron 1 
position +1 corresponding to assembly position 133,275,161. 
The cis/trans arrangement of variants c.318C>T–c.467C>T 
in Case 7 and variants c.796C>A–c.803G>C in Case 13 were 
determined by long-range polymerase chain reaction (PCR) 
(Takara Bio, Mountain View, CA) of gDNA, cloning into a 
bacterial host, and Sanger sequencing. Primer sequences are 
available upon request.
Case Reports and Results
ABO*A(28+1C)
Case 1: Typing of a probably white patient with a history 
of A subgroup yielded a forward group O, reverse group A 
discrepancy on two separate occasions by both gel and tube 
methods (Table 1). Sanger and next-generation sequencing of 
ABO detected variants c.28+1G>C and c.261delG in hetero-
zygosity. Variant c.28+1G>C alters the consensus sequence at 
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Table 1. ABO serology methods, reagents, and agglutination results
Forward testing Reverse testing
Case Method Phase Reagent Anti-A Anti-B Anti-A,B A1 RBCs A2 RBCs B RBCs
1 Gel Grifols 0 0 0 0 NT 4+
Tube IS Bio-Rad 0 0 0 0 NT 4+
2 Gel NA mf 0 NT 0 NT 4+
Tube IS Immucor 1+mf 0 1+mf 0 0 3+
RT Immucor 3+mf 0 3+mf 0 0 3+
3 Gel Ortho mf+ 0 NT 0 NT 4+
Tube NA NA W+ 0 NT 0 NT 3+
4 Gel Quotient 0 0 NT 0 NT 3+
Tube IS NA 1+mf 0 NT 0 NT 4+
5 Gel Grifols 0 0 NT NT NT NT
SP Immucor 0 0 NT 1+ NT 4+
Tube IS Grifols 0 0 0 0 NT 4+
Immucor 1+/2+mf 0 NT 0 NT 4+
Quotient 0 NT NT NT NT NT
6 Gel Bio-Rad 0 0 NT 0 NT 2+
Grifols 0 0 NT 0 NT 2+
4°C Bio-Rad NT NT NT 0 NT 3+
Tube 4°C Grifols NT NT NT 1+ NT 3+
Immucor NT NT NT 1+ NT 3+
7 Gel NA 0 0 NT 0/W+ 0/W+ NT
Tube IS Immucor 0 0 0/W+ 0 0 4+
Grifols NT NT NT 0 0 4+
Ortho 0 0 0 0 0 4+
RT Immucor 0 0 0 0 0 4+
Ortho 0 0 0 0 0 4+
8 Gel Ortho 0 +/– 0 3+ NT 0
Tube IS Bio-Rad 0 +/– +/– NT NT NT
Diagast 0 0 0 NT NT NT
4°C Ortho NT NT NT 3+ NT 0
9 NA NA NA NA NA NA NA NA NA
10 Gel Ortho 0 2+mf 2+mf 3+ NT 0
Tube IS Bio-Rad 0 2+mf 2+mf NT NT NT
Diagast 0 2+mf 2+mf NT NT NT
11 Gel Diamed 0 3+ 3+ 4+ NT 0
Ortho 0 0 2+mf 3+ NT 0
12 Gel Ortho 0 2+mf 2+mf 3+ NT 4+
13 Gel Ortho 0 4+ NT 0 0 0
SP Immucor 0 4+ NT 0 0 0
14 Gel Grifols 0 0 0 0 NT +
Ortho W+ 0 0 0 NT +
Tube IS Grifols 0 0 0 NT NT NT
15 Gel Bio-Rad 2+mf 0 2+mf NT NT NT
Ortho +/– 0 0 0 NT 3+
Tube IS Bio-Rad 0 0 0 NT NT NT
Diagast 0 0 0 NT NT NT
4°C Ortho NT NT NT 0 NT 3+
RBCs = red blood cells; IS = immediate spin; mf = mixed field; RT = room temperature; W = weak; SP = solid phase; +/– = equivocal; NT = not tested; NA = 
not applicable.
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the intron 1 donor splice site and is therefore predicted to impair 
mRNA maturation. From the discrepant group A serology, 
we infer the genotype to consist of alleles ABO*O.01.01 and 
ABO*A(28+1C) (Table 2), with ABO*A(28+1C) expressing 
reduced levels of A transferase.
ABO*A(28+5788T)
Cases 2–4: Typing of three white patients yielded the 
following phenotypes: Case 2: Forward mixed field with anti-A 
and anti-A,B by gel and tube methods, respectively, reverse 
group A; Case 3: Forward group Amixed field by gel method and 
group Aweak by tube method, reverse group A; Case 4: Forward 
group O by gel method and mixed field by tube method, reverse 
group A (Table 1). Next-generation sequencing of ABO detected 
the following variants: Case 2: c.28+5788C>T, c.261delG, and 
c.768C>A in heterozygosity; Cases 3 and 4: c.28+5788C>T, 
and c.261delG in heterozygosity. Variant c.28+5788C>T 
alters the sequence at an inverted GATA-1 transcription 
factor binding site in the intron 1 enhancer (Fig. 1) and is 
predicted to impair transcriptional activity. From the in 
trans arrangement of c.28+5788C>T with common ABO*O 
polymorphisms in the enhancer region and from the unusual 
group A serology, we infer the genotype of Case 2 to consist of 
alleles ABO*O.01.26 and ABO*A(28+5788T) and that of Cases 
3 and 4 of alleles ABO*O.01.01 and ABO*A(28+5788T) (Table 
2), with ABO*A(28+5788T) expressing reduced levels of A 
transferase.
ABO*A(28+5839A)
Case 5: Typing by tube method of an African-American 
patient with a history of multiple and recent transfusions yield-
ed a forward group O, reverse group A discrepancy (Table 1). 
Sanger sequencing of ABO detected variants c.28+5839G>A 
and c.261delG in heterozygosity. Variant c.28+5839G>A is 
located adjacent to a C/EBP binding site in the intron enhancer 
(Fig. 1), which could impair transcriptional activity. From the 
group A discrepant serology, we infer the genotype to consist 
of alleles ABO*O.01.01 and ABO*A(28+5839A) (Table 2), with 
ABO*A(28+5839A) expressing reduced levels of A transferase.
ABO*A(28+5855A)
Case 6: Typing of a white donor from Slovakia by gel 
method yielded a forward group O, reverse group A discrepan-
cy (Table 1). Reverse typing by tube method at 4°C yielded a 1+ 
result on A1 red blood cells (RBCs). Anti-A could be adsorbed 
and eluted from the patient’s RBCs, and her saliva contained H 
Table 2. Alleles, variants, and affected sites in ABO intron 1
Allele Variant Reference SNP Affected site GenBank† Case Allele in trans
ABO*A(28+1C) c.28+1G>C — Splice donor MW281468 1 ABO*O.01.01
ABO*A(28+5788T) c.28+5788C>T — Inverted GATA MW281466 2 ABO*O.01.26
3 ABO*O.01.01
4 ABO*O.01.01
ABO*A(28+5839A) c.28+5839G>A rs1588646575‡ C/EBP§ MW281465 5 ABO*O.01.01
ABO*A(28+5855A) c.28+5855G>A — GATA MW281467 6 ABO*O.01.02
ABO*A(28+5856G) c.28+5856A>G — GATA MW273371 7 ABO*O.01.09
ABO*B(28+5873T) c.28+5873C>T — RUNX1 MW273373 8 ABO*O.01.41
9 ABO*O.01.02
ABO*B(28+5874G) c.28+5874A>G — RUNX1 MW273374 10 ABO*O.01.01
11 ABO*O.01.02
12 ABO*O.01.68(595T)
ABO*A(29–5G) c.29–5T>G — Splice acceptor MW273372 13 ABO*B.01
14 ABO*O.01.01
15 ABO*O.01.02
SNP = single nucleotide polymorphism.
†Accession identification.
‡ The publicly available frequencies for rs1588646575 are 1/2969 Korean (KRDGB database ID: ss3921124244) and 0/10680 (www.ncbi.nlm.nih.gov/snp/
docs/gsr/alfa).
§Position c.28+5839 may be within or adjacent to the consensus C/EBP site (Fig. 2).
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and A substances. Sanger and next-generation sequencing of 
ABO detected variants c.28+5855G>A, c.106G>T, c.188G>A, 
c.189C>T, c.220C>T, c.261delG, c.297A>G, c.646T>A, 
c.681G>A, c.771C>T, and c.829G>A in heterozygosity. Variant 
c.28+5855G>A alters the sequence at a GATA-1 transcription 
factor binding site in the intron 1 enhancer (Fig. 1) and is 
therefore predicted to impair transcriptional activity. From 
the in trans arrangement of c.28+5855G>A with common 
ABO*O polymorphisms (data not shown) and from the 
discrepant group A serology, we infer the genotype to consist 
of alleles ABO*O.01.02 and ABO*A(28+5855A) (Table 2), with 
ABO*A(28+5855A) expressing reduced levels of A transferase 
in erythroid cells.
ABO*A(28+5856G)
Case 7: Typing of a Hispanic donor by gel method yielded 
a forward group O, reverse group A/Aweak discrepancy, and by 
tube method with various reagents a forward group O/group 
Aweak, reverse group A discrepancy (Table 1). Sanger sequenc-
ing of genomic DNA and cloned ABO exons 6–7 DNA detected 
variants c.28+5856A>G, c.261delG, c.318C>T, and c.467C>T 
in heterozygosity. Variant c.28+5856A>G alters a GATA-1 
transcription factor binding site in the intron 1 enhancer 
(Fig. 1) and is therefore predicted to impair transcriptional 
activity. From the discrepant group A serology, we infer the 
genotype to consist of alleles ABO*O.01.09 (which includes the 
coding-sequence variants) and ABO*A(28+5856G) (Table 2), 
with ABO*A(28+5856G) expressing reduced levels of A 
transferase.
ABO*B(28+5873T)
Cases 8 and 9: Typing of two patients of unknown race 
yielded group B phenotype discrepancies. For Case 8, in 
particular, forward testing showed group O or group B+/– 
by gel and tube methods, and reverse testing showed group 
B (Table 1). In Case 8, Sanger sequencing of ABO detected 
variants c.28+5873C>T, c.261delG, c.297A>G, c.526C>G, 
c.657C>T, c.703G>A, c.796C>A, c.803G>C, and c.930G>A 
in heterozygosity. In Case 9, next-generation sequencing of 
ABO detected variants c.28+5873C>T, c.106G>T, c.188G>A, 
c.189C>T, c.220C>T, c.261delG, c.526C>G, c.646T>A, 
c.657C>T, c.681G>A, c.703G>A, c.771C>T, c.796C>A, 
c.803G>C, c.829G>A, and c.930G>A in heterozygosity and 
c.297A>G in homozygosity. Variant c.28+5873C>T alters 
a RUNX1 transcription factor binding site at the intron 
1 enhancer (Fig. 1) and is therefore predicted to impair 
transcriptional activity. From the variants detected, we infer 
the genotype of Case 8 to consist of alleles ABO*O.01.41 and 
Fig. 1 Graphic representation of ABO exons 1–7, transcription factor binding sites in the intron 1 enhancer element, and abbreviated intron 
1 variants. Top and bottom: Variants on ABO*A and ABO*B backgrounds, respectively. Above the DNA lines, previously reported variants. 
Below the DNA lines, variants described in this report.
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ABO*B(28+5873T). From the variants detected and the cis/
trans arrangement of c.28+5873C>T with common ABO*O 
polymorphisms (data not shown), we infer the genotype of Case 
9 to consist of alleles ABO*O.01.02 and ABO*B(28+5873T) 
(Table 2). Based on the discrepant group B serology of Case 8, 
ABO*B(28+5873T) is predicted to express reduced levels of B 
transferase.
ABO*B(28+5874G)
Cases 10–12: Typing of three patients from Italy, two 
white and one of unknown race, yielded group B phenotype 
discrepancies (Table 1). Sanger sequencing of ABO detected 
the following variants: Case 10: c.28+5874A>G, c.261delG, 
c.297A>G, c.526C>G, c.657C>T, c.703G>A, c.796C>A, 
c.803G>C, and c.930G>A in heterozygosity; Case 11: 
c.28+5874A>G, c.106G>T, c.188G>A, c.189C>T, c.220C>T, 
c.261delG, c.526C>G, c.646T>A, c.657C>T, c.681G>A, 
c.703G>A, c.771C>T, c.796C>A, c.803G>C, c.829G>A, and 
c.930G>A in heterozygosity and c.297A>G in homozygosity; 
Case 12: c.28+5874A>G, c.106G>T, c.188G>A, c.189C>T, 
c.261delG, c.526C>G, c.595C>T, c.646T>A, c.657C>T, 
c.681G>A, c.703G>A, c.771C>T, c.796C>A, c.803G>C, 
c.829G>A, and c.930G>A in heterozygosity and c.297A>G in 
homozygosity. Variant c.28+5874A>G alters the sequence of 
a RUNX1 transcription factor site in the intron 1 enhancer 
(Fig. 1) and is therefore predicted to impair transcriptional 
activity. From the variants detected and the discrepant group 
B serology, we infer the genotype of the three cases to include 
allele ABO*B(28+5874G), with the discrepant serology due to 
reduced expression of B transferase by this allele and in trans 
alleles ABO*O.01.01 (Case 10), ABO*O.01.02 (Case 11), and 
ABO*O.01.68(595T) (Case 12) (Table 2).
ABO*A(29–5G)
Cases 13–15: Typing of two patients of unknown race 
and a white donor, all from Italy, yielded group A phenotype 
discrepancies (Table 1). Sanger sequencing of ABO detected 
the following variants in heterozygosity: Case 13: c.29-
5T>G, c.297A>G, c.526C>G, c.657C>T, c.703G>A, c.796C>A, 
c.803G>C, and c.930G>A; Case 14: c.29-5T>G, and c.261delG; 
Case 15: c.29-5T>G, c.106G>T, c.188G>A, c.189C>T, c.220C>T, 
c.261delG, c.297A>G, c.646T>A, c.681G>A, c.771C>T, and 
c.829G>A. Variant c.29-5T>G alters the consensus sequence 
at the intron 1 acceptor splice site and is therefore predicted to 
impair mRNA maturation. From the variants detected and the 
discrepant group A serology, we infer the genotype of the three 
cases to include allele ABO*A(29–5G), with the discrepant 
serology due to reduced expression of A transferase by this 
allele, and in trans alleles ABO*B.01 (Case 13), ABO*O.01.01 
(Case 14), and ABO*O.01.02 (Case 15) (Table 2).
Discussion
To the best of our knowledge, ABO*A(28+5788T) is the 
first allele with a variant at the inverted GATA-1 site (positions 
c.28+5784 to c.28+5789 in the intron 1 enhancer element) 
found in association with an altered ABO phenotype.
Based on the alignment of direct and inverted versions of 
ABO*A(28+5839A) sequence to the C/EBP consensus binding 
site (Fig. 2), variant c.28+5839G>A has the potential to alter 
the consensus sequence at this site and lead to an altered ABO 
phenotype. However, because it does not affect any of the 
major consensus positions of the C/EBP site, it is also possible 
that additional variant(s) outside of the sequenced regions are 
responsible for the observed phenotype.
Fig. 2 Two alignments of direct (sense strand) and inverted (anti-
sense strand) sequences at positions c.28+5829–c.28+5840 of 
the ABO*A(28+5839A) allele with the transcription factor flexible 
model of the C/EBP binding site consensus sequence.17 Letter size 
represents the probability of a particular nucleotide at each position. 
Circled letters indicate variant sequence at position c.28+5839.
Alleles ABO*B(28+5855A) and ABO*A(28+5855C), 
which alter the sequence of the direct GATA-1 site (positions 
c.28+5854 to c.28+5859 in the intron 1 enhancer element), 
have been associated with Bm13 and Am8 phenotypes, respec-
tively. Thus, it seems likely that the transferase encoded by 
ABO*A(28+5855A) (Case 6) leads to an Am phenotype. Because 
alleles ABO*A(28+5857G) and ABO*B(28+5857G) have been 
associated with Am16 and Bm4 phenotypes, respectively, this 
inference can also be extended to allele ABO*A(28+5856G) 
(Case 7).
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Alleles ABO*B(28+5871T), ABO*B(28+5872C), ABO*B 
(28+5874G), and ABO*A(28+5876G), characterized by RUNX1 
site variants, have been reported to encode Bweak/B311,14 and A35 
phenotype transferases, respectively. The mixed-field serology 
detected with anti-B reagents for Cases 10–12, which harbor 
RUNX1 variant allele ABO*B(28+5874G), is consistent with 
those observations.
Alleles ABO*B(28+2_3insT) and ABO*B(28+5C), 
characterized by donor splice site variants, have been 
associated with Bvery weak1 and Bel2 phenotypes, respectively. 
Because position +1 often plays a more critical role in mRNA 
splicing than positions +3 or +5, it seems likely that allele 
ABO*A(28+1C) (Case 1) encodes an O- or Ael-phenotype 
transferase.
Conclusion
The numerous variants identified in the ABO intron 1 
enhancer element with an effect on transferase expression 
highlight its key regulatory role. The frequency of cases with 
such variants supports the inclusion of this element among the 
regions interrogated by ABO genotyping assays.
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